Article
Pediatrics
Tingyan He, Yu Xia, Ying Luo, Jun Yang
Summary: This study aimed to evaluate the efficacy and potential adverse effects of JAKi in patients with systemic juvenile idiopathic arthritis (SJIA). The results showed that JAKi may be an alternative or adjuvant agent for patients with persistently active disease, glucocorticoid-related adverse reactions, or SJIA-MAS.
FRONTIERS IN PEDIATRICS
(2023)
Article
Cell Biology
Justine Maller, Terry Morgan, Mayu Morita, Frank McCarthy, Yunshin Jung, Katrin J. Svensson, Joshua E. Elias, Claudia Macaubas, Elizabeth Mellins
Summary: The study suggests that intercellular communication mediated by extracellular vesicles plays an important role in the pathogenesis of systemic juvenile idiopathic arthritis. The number and cellular sources of extracellular vesicles differ between the active and inactive states of the disease and healthy controls.
JOURNAL OF LEUKOCYTE BIOLOGY
(2023)
Review
Rheumatology
Claas H. Hinze, Dirk Foell, Christoph Kessel
Summary: Systemic juvenile idiopathic arthritis (sJIA) is a disease characterized by severe systemic inflammation and arthritis. It poses challenges to rheumatologists treating pediatric and adult patients worldwide. Although treatment plans exist for classic sJIA, there is still a lack of clear treatment approaches for early sJIA without arthritis and complicated sJIA.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Review
Immunology
Bert Malengier-Devlies, Mieke Metzemaekers, Carine Wouters, Paul Proost, Patrick Matthys
Summary: Neutrophils play a crucial role in the innate immune system, using both oxidative and non-oxidative defense mechanisms to eradicate pathogens, and also act as decision shaping cells guiding other leukocytes for immune responses. The development and release of neutrophils are tightly regulated under both homeostatic and emergency conditions.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
William G. Ambler, Kabita Nanda, Karen Brandt Onel, Susan Shenoi
Summary: This review focuses on the treatment options and potential future therapeutics for systemic juvenile idiopathic arthritis (SJIA). Recent advancements in targeted therapies have improved patient outcomes, but there are still subsets of patients with refractory disease and severe complications.
ANNALS OF MEDICINE
(2022)
Article
Health Care Sciences & Services
Amelia J. Garner, Reza Saatchi, Oliver Ward, Daniel P. Hawley
Summary: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children, requiring prompt and accurate diagnosis due to its potential for chronic damage and functional disability. Recent studies have demonstrated the potential value of novel tools and techniques in assessing and monitoring JIA, but additional research is needed to confirm their clinical utility.
Article
Medicine, General & Internal
Monika Ostrowska, Emil Michalski, Piotr Gietka, Malgorzata Manczak, Magdalena Posadzy, Iwona Sudol-Szopinska
Summary: This study compared MRI findings between patients clinically suspected of Juvenile Idiopathic Arthritis (JIA) and patients with ankle arthralgia of unknown cause. The results showed that inflammatory features were observed on MRI, with tenosynovitis being significantly more common in JIA patients. However, the MRI summarized score did not effectively differentiate between JIA and non-JIA patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Arianna De Matteis, Claudia Bracaglia, Denise Pires Marafon, Anna Lucia Piscitelli, Maria Alessio, Roberta Naddei, Francesca Orlando, Giovanni Filocamo, Francesca Minoia, Angelo Ravelli, Jessica Tibaldi, Rolando Cimaz, Achille Marino, Gabriele Simonini, Maria Vincenza Mastrolia, Francesco La Torre, Ilaria Tricarico, Francesco Licciardi, Davide Montin, Maria Cristina Maggio, Clotilde Alizzi, Giorgia Martini, Adele Civino, Romina Gallizzi, Alma Nunzia Olivieri, Francesca Ardenti Morini, Giovanni Conti, Fabrizio De Benedetti, Manuela Pardeo
Summary: This study used real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with sJIA. The results showed that canakinumab was effective in treating sJIA and had no serious adverse events. The history of MAS and higher number of active joints were associated with poorer treatment outcomes.
Article
Pediatrics
Lili Ye, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Chenxi Liu, Shengfang Bao, Jing Wu, Yanliang Jin
Summary: This study explored the role of DKK-1 and SOST in the pathogenesis of JIA. It was found that plasma levels of DKK-1 were significantly higher in JIA patients, especially in those with HLA-B27 positivity. After treatment, DKK-1 levels decreased significantly. However, there was no significant change in SOST levels among different JIA subtypes, before and after treatment, and healthy controls.
PEDIATRIC RESEARCH
(2023)
Article
Pediatrics
Ellen Go, Mira van Veenendaal, Cedric Manlhiot, Rayfel Schneider, Brian W. McCrindle, Rae S. M. Yeung
Summary: This study describes the disease course of a small proportion of patients with both Kawasaki disease and systemic juvenile idiopathic arthritis, characterized by refractory Kawasaki disease, high prevalence of coronary artery dilatation, and shared immunopathology potentially linking the two conditions.
FRONTIERS IN PEDIATRICS
(2021)
Review
Medicine, General & Internal
Duilio Petrongari, Paola Di Filippo, Francesco Misticoni, Giulia Basile, Sabrina Di Pillo, Francesco Chiarelli, Marina Attanasi
Summary: Systemic juvenile idiopathic arthritis associated with lung disorders (sJIA-LD) is a subtype of sJIA characterized by chronic life-threatening pulmonary disorders. It was exceptionally rare before 2013, but the reported prevalence is now approximately 6.8%. Clinically, children with sJIA-LD exhibit relatively mild symptoms, but the severity of pulmonary inflammation is high. sJIA-LD is often associated with early onset, macrophage activation syndrome, and high interleukin-18 circulating levels.
Review
Rheumatology
Eduardo Liquidano-Perez, Gibert Maza-Ramos, Jose Luis Salazar-Bailon, Marco Antonio Yamazaki-Nakashimada, Francisco Rivas-Larrauri
Summary: This study presents a refractory case of soJIA complicated with MAS successfully treated with plasma exchange, resulting in significant improvement.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Nicolino Ruperto, Hermine Brunner, Athimalaipet Ramanan, Gerd Horneff, Ruben Cuttica, Michael Henrickson, Jordi Anton, Alina Lucica Boteanu, Inmaculada Calvo Penades, Kirsten Minden, Heinrike Schmeling, Markus Hufnagel, Jennifer E. Weiss, Manuela Pardeo, Kabita Nanda, Johannes Roth, Nadina Rubio-Perez, Joy C. Hsu, Sunethra Wimalasundera, Chris Wells, Kamal Bharucha, Wendy Douglass, Min Bao, Navita L. Mallalieu, Alberto Martini, Daniel Lovell, Fabrizio De Benedetti
Summary: The study found that the dosing regimens of s.c. tocilizumab in systemic JIA and polyarticular JIA are similar to i.v. tocilizumab with good efficacy. Additionally, the subcutaneous administration route is more convenient and suitable for at-home use.
Article
Rheumatology
Justine Maller, Emily Fox, K. T. Park, Sarah Sertial Paul, Kevin Baszis, Charlotte Borocco, Sampath Prahalad, Pierre Quartier, Adam Reinhardt, Dieneke Schonenberg-Meinema, Lauren Shipman-Duensing, Maria Teresa Terreri, Julia Simard, Idit Lavi, Elizabeth Chalom, Joyces Hsu, Devy Zisman, Elizabeth D. Mellins
Summary: The occurrence of inflammatory bowel disease in the setting of systemic juvenile idiopathic arthritis is rare, with patients showing favorable response to tumor necrosis factor-alpha inhibitors.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Stephane Mitrovic, Nolan Hassold, Aly Kamissoko, Nicolas Rosine, Alexis Mathian, Guillaume Mercy, Edouard Pertuiset, Gaetane Nocturne, Bruno Fautrel, Isabelle Kone-Paut
Summary: A retrospective national survey revealed features of SpA in patients with SJIA/AOSD, with a prevalence of 6.58% in AOSD patients and 10% in SJIA patients. This suggests a possible overlap between SpA and AOSD that requires further study.